Pharmaceutical formulation comprising a low molecular weight...

Details Pharmaceutical formulation comprising a low molecular weight... Pharmaceutical formulation comprising a low molecular weight...

2005-11-08

2005-11-08

Weber, Jon (Department: 1653)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C514S020800, C514S247000, C424S009100, C544S238000, C544S239000, C544S240000, C560S034000, C560S035000, C560S168000, C560S169000, C562S439000, C562S560000

Reexamination Certificate

active

06962905

ABSTRACT:
A kit of parts containing (a) a pharmaceutical formulation including a low molecular weight thrombin inhibitor, or a pharmaceutically acceptable derivative thereof, in admixture with a pharmaceutically acceptable adjuvant, diluent or carrier, and (b) a pharmaceutical formulation including a prodrug of a low molecular weight thrombin inhibitor, or a pharmaceutically acceptable derivative of that prodrug, in admixture with a pharmaceutically acceptable adjuvant, diluent or carrier. Components (a) and (b) are each provided in a form that is suitable for administration in conjunction with the other. The kit is useful in the treatment of conditions in which inhibition of thrombin is required or desired.

REFERENCES:
patent: 4346078 (1982-08-01), Bajusz et al.
patent: 5705487 (1998-01-01), Schacht et al.
patent: 5707966 (1998-01-01), Schacht et al.
patent: 5710130 (1998-01-01), Schacht et al.
patent: 5795892 (1998-08-01), Von Der Saal et al.
patent: 5824679 (1998-10-01), Von Der Saal et al.
patent: 6087380 (2000-07-01), Hauel et al.
patent: 6602871 (2003-08-01), Lam et al.
patent: 2156729 (1994-09-01), None
patent: 0 195 212 (1986-09-01), None
patent: 0 293 881 (1988-12-01), None
patent: 0 362 002 (1990-04-01), None
patent: 0 526 877 (1993-02-01), None
patent: 0 526 877 (1993-02-01), None
patent: 0 530 167 (1993-03-01), None
patent: 0 542 525 (1993-05-01), None
patent: 0 601 459 (1994-06-01), None
patent: 0 623 596 (1994-11-01), None
patent: 0 648 780 (1995-04-01), None
patent: 0 669 317 (1995-08-01), None
patent: 0686042 (1995-12-01), None
patent: 0687253 (1998-12-01), None
patent: 0 364 344 (1999-04-01), None
patent: 262 725 (1997-05-01), None
patent: 94/20467 (1944-09-01), None
patent: 93/05069 (1993-03-01), None
patent: 93/11152 (1993-06-01), None
patent: 93/18060 (1993-09-01), None
patent: 94/29336 (1995-08-01), None
patent: 95/23609 (1995-08-01), None
patent: 95/35309 (1995-12-01), None
patent: 96/03374 (1996-02-01), None
patent: 96/06832 (1996-03-01), None
patent: 96/06849 (1996-03-01), None
patent: 96/16671 (1996-06-01), None
patent: 96/25426 (1996-08-01), None
patent: 96/31504 (1996-10-01), None
patent: 96/32110 (1996-10-01), None
patent: 97/01338 (1997-01-01), None
patent: 97/02284 (1997-01-01), None
patent: 97/11693 (1997-04-01), None
patent: 97/15190 (1997-05-01), None
patent: 97/23499 (1997-07-01), None
patent: 97/24135 (1997-07-01), None
patent: 97/30708 (1997-08-01), None
patent: 97/40024 (1997-10-01), None
patent: 97/46577 (1997-12-01), None
patent: 97/47299 (1997-12-01), None
patent: 97/49404 (1997-12-01), None
patent: 98/01422 (1998-01-01), None
patent: 98/06740 (1998-02-01), None
patent: 98/06741 (1998-02-01), None
patent: 98/37075 (1998-08-01), None
patent: 98/57932 (1998-12-01), None
patent: 99/00371 (1999-01-01), None
patent: 99/28297 (1999-06-01), None
patent: 99/29664 (1999-06-01), None
patent: 99/29670 (1999-06-01), None
patent: 99/37611 (1999-07-01), None
patent: 99/37668 (1999-07-01), None
patent: 99/40072 (1999-08-01), None
patent: 99/54313 (1999-10-01), None
patent: 00/01704 (2000-01-01), None
patent: 00/08014 (2000-02-01), None
Claeson, G., “Synthetic peptides and peptidomimeics . . . ,” Blood Coagulation and Fibrinolysis, vol. 5, pp. 411-436 (1994).
“Prevention of Venous Thromboembolis,” Chest, vol. 114, No. 5, pp. 531S-560S (1998).
Eriksson et al, “Prevention of deep-vein thrombosis after . . . ,” Lancet, vol. 347, pp. 635-639 (1996).
Eriksson et al., “Pharmacokinetics and Pharmacodynamics . . . ” Thromb Haemost, vol. 81, pp. 358-363 (1999).
Ignasiak et al,“ Effects of Intravenous Enoxaparin and Intravenous . . . ,” Journal of Thrombosis and Thromolysis, vol. 6, pp. 199-200 (1998).
Davidson, Bruce; “1995 American College of Chest Phsyicians (ACCP) Consensus Guidelines on Antithrombotic Therapy”; Seminars in Thrombosis and Hemostasis, 22 Suppl. 2 (1996) 1.
Clagett, G.P., et al; “Prevention of Venous Thromboembolism”; Fourth ACCP Consensus Conference on Antithrombotic Therapy, Chest, 108 (1995) 312S.

Affiliated with

Also associated with

Rating

Pharmaceutical formulation comprising a low molecular weight... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Pharmaceutical formulation comprising a low molecular weight..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pharmaceutical formulation comprising a low molecular weight... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3458511